Evidence map›Paper›PMID 34718737›Full record

ArticleNucleic acids research2022

The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials.

Simon D Harding, Jane F Armstrong, Elena Faccenda, Christopher Southan, Stephen P H Alexander, Anthony P Davenport, Adam J Pawson, Michael Spedding, Jamie A Davies, NC-IUPHAR

Open access · goldAbstract readDataset
In one paragraph

Article in Nucleic acids research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 1 pooled it
20.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 1 synthesis or guideline pooled it, 157 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. The IUPHAR/BPS Guide to PHARMACOLOGY in 2026.Nucleic acids research · 2026
    Article
  7. Review
  8. Early Life Injury Alters Spinal Astrocyte Development.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Simon D HardingDeanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK.ORCID 0000-0002-9262-8318
Jane F ArmstrongDeanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK.ORCID 0000-0002-0524-0260
Elena FaccendaDeanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK.ORCID 0000-0001-9855-7103
Christopher SouthanDeanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK.ORCID 0000-0001-9580-0446
Stephen P H AlexanderSchool of Life Sciences, University of Nottingham Medical School, Nottingham NG7 2UH, UK.ORCID 0000-0003-4417-497X
Anthony P DavenportExperimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0002-2096-3117
Adam J PawsonDeanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK.ORCID 0000-0003-2280-845X
Michael SpeddingSpedding Research Solutions SAS, Le Vésinet 78110, France.ORCID 0000-0002-1248-8221
Jamie A DaviesDeanery of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, UK.ORCID 0000-0001-6660-4032
NC-IUPHAR
University of Edinburgh · GBUniversity of Cambridge · GBUniversity of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb; www.guidetopharmacology.org) is an open-access, expert-curated database of molecular interactions between ligands and their targets. We describe expansion in content over nine database releases made during the last two years, which has focussed on three main areas of infection. The COVID-19 pandemic continues to have a major impact on health worldwide. GtoPdb has sought to support the wider research community to understand the pharmacology of emerging drug targets for SARS-CoV-2 as well as potential targets in the host to block viral entry and reduce the adverse effects of infection in patients with COVID-19. We describe how the database rapidly evolved to include a new family of Coronavirus proteins. Malaria remains a global threat to half the population of the world. Our database content continues to be enhanced through our collaboration with Medicines for Malaria Venture (MMV) on the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY (www.guidetomalariapharmacology.org). Antibiotic resistance is also a growing threat to global health. In response, we have extended our coverage of antibacterials in partnership with AntibioticDB.

Indexed as

COVID-19 Drug TreatmentAnti-Bacterial AgentsAntimalarialsAntiviral AgentsCOVID-19Databases, PharmaceuticalData CurationHumansLigandsMalariaUser-Computer InterfaceViral ProteinsAnti-Bacterial AgentsAntimalarialsAntiviral AgentsLigandsViral Proteins

Identifiers

PMID34718737
PMCPMC8689838
OpenAlexW3209896479

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.